

# Myla D Goldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5112842/publications.pdf>

Version: 2024-02-01

73  
papers

3,353  
citations

186265  
28  
h-index

149698  
56  
g-index

80  
all docs

80  
docs citations

80  
times ranked

3677  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. <i>Multiple Sclerosis Journal</i> , 2008, 14, 383-390.	3.0	535
2	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	10.2	238
3	Validity of performance scales for disability assessment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1176-1182.	3.0	237
4	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 846-855.	27.0	201
5	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	7.6	139
6	Clinically meaningful performance benchmarks in MS. <i>Neurology</i> , 2013, 81, 1856-1863.	1.1	131
7	Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 229-239.	3.5	125
8	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	10.2	110
9	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 94-105.	3.0	95
10	Leptin Indirectly Affects Estrous Cycles by Increasing Metabolic Fuel Oxidation. <i>Hormones and Behavior</i> , 1998, 33, 217-228.	2.1	90
11	Pilot study of a ketogenic diet in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e565.	6.0	82
12	Physical inactivity, neurological disability, and cardiorespiratory fitness in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 98-104.	2.1	71
13	Clinical Importance of Steps Taken per Day among Persons with Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e73247.	2.5	65
14	Walking impairment in patients with multiple sclerosis: exercise training as a treatment option. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 767.	2.2	61
15	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2016, 50, 166-177.	1.8	59
16	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. <i>Neurology</i> , 2019, 93, e1921-e1931.	1.1	58
17	Evidence for the different physiological significance of the 6- and 2-minute walk tests in multiple sclerosis. <i>BMC Neurology</i> , 2012, 12, 6.	1.8	53
18	Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 91-102.	1.3	52

#	ARTICLE	IF	CITATIONS
19	Accelerometry and Its Association With Objective Markers of Walking Limitations in Ambulatory Adults With Multiple Sclerosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2010, 91, 1942-1947.	0.9	51
20	Multiple Sclerosis Walking Scale-12 and oxygen cost of walking. <i>Gait and Posture</i> , 2010, 31, 506-510.	1.4	50
21	Oxygen cost of treadmill and over-ground walking in mildly disabled persons with multiple sclerosis. <i>Neurological Sciences</i> , 2011, 32, 255-262.	1.9	50
22	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. <i>Journal of the American College of Radiology</i> , 2017, 14, 371-379.e1.	1.8	49
23	Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data. <i>Multiple Sclerosis Journal</i> , 2010, 16, 868-877.	3.0	41
24	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1469-1484.	3.0	41
25	Quantifying six-minute walk induced gait deterioration with inertial sensors in multiple sclerosis subjects. <i>Gait and Posture</i> , 2016, 49, 340-345.	1.4	40
26	PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. <i>Neurology: Clinical Practice</i> , 2016, 6, e17-e19.	1.6	39
27	A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 54-57.	2.0	34
28	Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 989-998.	2.4	32
29	Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1405-1414.	3.0	32
30	Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 47-49.	2.0	30
31	Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 637-644.	1.9	29
32	Remotely engaged: Lessons from remote monitoring in multiple sclerosis. <i>International Journal of Medical Informatics</i> , 2017, 100, 26-31.	3.3	28
33	Breastfeeding During Infancy Is Associated With a Lower Future Risk of Pediatric Multiple Sclerosis. <i>Pediatric Neurology</i> , 2017, 77, 67-72.	2.1	27
34	Does a waist-worn accelerometer capture intra- and inter-person variation in walking behavior among persons with multiple sclerosis?. <i>Medical Engineering and Physics</i> , 2010, 32, 1224-1228.	1.7	22
35	Body mass index trajectories in pediatric multiple sclerosis. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 1289-1294.	2.1	21
36	Vitamin D status and age of onset of demyelinating disease. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 684-688.	2.0	20

#	ARTICLE	IF	CITATIONS
37	Validation of the NARCOMS Registry. <i>International Journal of MS Care</i> , 2011, 13, 114-120.	1.0	19
38	Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. <i>Clinical Therapeutics</i> , 2015, 37, 2780-2787.	2.5	19
39	Fatigue and fluid hydration status in multiple sclerosis: A hypothesis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1438-1443.	3.0	18
40	Deepmotion: a deep convolutional neural network on inertial body sensors for gait assessment in multiple sclerosis. , 2016, , .		17
41	Real-world walking in multiple sclerosis: Separating capacity from behavior. <i>Gait and Posture</i> , 2018, 59, 211-216.	1.4	17
42	The e-MSWS-12: improving the multiple sclerosis walking scale using item response theory. <i>Quality of Life Research</i> , 2016, 25, 3221-3230.	3.1	16
43	Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. <i>PLoS ONE</i> , 2020, 15, e0228617.	2.5	16
44	Causal analysis of inertial body sensors for enhancing gait assessment separability towards multiple sclerosis diagnosis. , 2015, , .		15
45	Multiple sclerosis: treating symptoms, and other general medical issues.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 177-186.	1.3	15
46	Causality Analysis of Inertial Body Sensors for Multiple Sclerosis Diagnostic Enhancement. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1273-1280.	6.3	14
47	The state of clinical research in neurology. <i>Neurology</i> , 2018, 90, e1347-e1354.	1.1	14
48	Statins to treat multiple sclerosis. <i>Neurology</i> , 2008, 71, 1386-1387.	1.1	13
49	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1281-1291.	3.0	13
50	Understanding the Physiological Significance of Four Inertial Gait Features in Multiple Sclerosis. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2018, 22, 40-46.	6.3	13
51	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 48.	9.0	11
52	Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 138-145.	1.0	11
53	The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731984614.	1.0	9
54	Retrospective cohort study of the relationship between systolic blood pressure variability and multiple sclerosis disability. <i>BMJ Open</i> , 2020, 10, e034355.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Gait Speed Trajectory During the Six-Minute Walk Test in Multiple Sclerosis: A Measure of Walking Endurance. <i>Frontiers in Neurology</i> , 2021, 12, 698599.	2.4	9
56	The Accuracy of Minimum Data Set Diagnoses in Describing Recent Hospitalization at Acute Care Facilities. <i>Journal of the American Medical Directors Association</i> , 2006, 7, 212-218.	2.5	8
57	Correlations between Inertial Body Sensor Measures and Clinical Measures in Multiple Sclerosis. , 2015, , .		6
58	Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk test. , 2016, 2016, 4959-4962.		5
59	Misdiagnosis of Migraine. <i>Headache</i> , 2003, 43, 85-86.	3.9	3
60	Multiple sclerosis, immunomodulation, and immunizations. <i>Neurology</i> , 2015, 84, 864-865.	1.1	3
61	Determining physiological significance of inertial gait features in multiple sclerosis. , 2016, , .		3
62	Glucocorticoid-associated blood glucose response and MS relapse recovery. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e378.	6.0	3
63	Evaluation of Treatment Practices for Urinalyses and Urine Cultures at an Outpatient Multiple Sclerosis Clinic. <i>International Journal of MS Care</i> , 2021, 23, 234-238.	1.0	3
64	No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 264-5.	4.5	2
65	Relationship between kernel density function estimates of gait time series and clinical data. , 2017, , .		2
66	Cerebellar syndrome in a man treated with natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e546.	6.0	2
67	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. <i>Multiple Sclerosis Journal</i> , 2022, 28, 817-830.	3.0	2
68	Relationship between balance confidence and social engagement in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103440.	2.0	2
69	Longitudinal estimation of gait time series density in multiple sclerosis subjects using inertial data. , 2016, , .		1
70	Demonstrating the real-world significance of the mid-swing to heel strike part of the gait cycle using spectral features. , 2017, , .		1
71	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. <i>Neurology: Clinical Practice</i> , 2021, 11, 352-357.	1.6	1
72	Smoking Beyond Multiple Sclerosis Diagnosis. <i>JAMA Neurology</i> , 2015, 72, 1105.	9.0	0

#	ARTICLE	IF	CITATIONS
73	Adaptive symptom reporting for mobile patient-reported disability assessment. , 2016, , .		0